Nichi-Iko Pharmaceutical Co., Ltd.

Informe acción TSE:4541

Capitalización de mercado: JP¥24.6b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nichi-Iko Pharmaceutical Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

-87.4%

Tasa de crecimiento de los beneficios

-86.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 3.4%
Tasa de crecimiento de los ingresos2.6%
Rentabilidad financieran/a
Margen neto-87.7%
Última actualización de beneficios31 Dec 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Nichi-Iko Pharmaceutical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

TSE:4541 Ingresos, gastos y beneficios (JPY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 22182,880-160,43929,0734,772
30 Sep 22184,379-145,20828,1254,655
30 Jun 22183,179-105,40727,8675,173
31 Mar 22179,060-104,98427,8794,248
31 Dec 21184,265-19,66727,1164,029
30 Sep 21184,518-18,91827,4384,275
30 Jun 21185,896-8,24627,1964,349
31 Mar 21188,218-4,17927,0294,335
31 Dec 20186,759-60626,5894,246
30 Sep 20188,1882,27325,7084,040
30 Jun 20188,8183,61025,6283,749
31 Mar 20190,0765,13325,6144,261
31 Dec 19181,5305,48224,1733,859
30 Sep 19175,7655,25023,8693,688
30 Jun 19170,8376,21623,3333,571
31 Mar 19166,5926,86422,5043,503
31 Dec 18148,4759,317-9817,065
30 Sep 18152,76610,2417,7596,382
30 Jun 18158,4828,56715,4845,687
31 Mar 18164,7178,07023,1364,467
31 Dec 17189,5637,38846,0477,263
30 Sep 17182,5185,05943,8557,263
30 Jun 17173,8564,75242,5847,263
31 Mar 17163,3724,78840,1127,263
31 Dec 16152,4683,64740,8824,874
30 Sep 16149,6779,59538,8374,874
30 Jun 16146,49310,73636,6314,874

Ingresos de calidad: 4541 is currently unprofitable.

Margen de beneficios creciente: 4541 is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 4541 is unprofitable, and losses have increased over the past 5 years at a rate of 87.4% per year.

Acelerando crecimiento: Unable to compare 4541's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 4541 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.6%).


Rentabilidad financiera

Alta ROE: 4541's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado